Maxim Group analyst Jason McCarthy maintained a Buy rating on RenovoRx (RNXT – Research Report) yesterday and set a price target of $9.00. The company’s shares closed yesterday at $2.10.
According to TipRanks, McCarthy is an analyst with an average return of -27.3% and a 21.82% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Lineage Therap, SELLAS Life Sciences Group, and Achieve Life Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RenovoRx with a $9.00 average price target.
See today’s best-performing stocks on TipRanks >>
Based on RenovoRx’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $3.26 million. In comparison, last year the company had a GAAP net loss of $3 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem.
Read More on RNXT:
